Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 8 | 2024 | 168 | 4.370 |
Why?
|
| Radiosurgery | 18 | 2025 | 360 | 3.160 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2025 | 23 | 2.620 |
Why?
|
| Head and Neck Neoplasms | 6 | 2025 | 140 | 2.570 |
Why?
|
| Palliative Care | 4 | 2026 | 52 | 2.490 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 71 | 2.070 |
Why?
|
| Brain Neoplasms | 14 | 2020 | 649 | 1.890 |
Why?
|
| Tonsillar Neoplasms | 2 | 2024 | 6 | 1.640 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2023 | 36 | 1.520 |
Why?
|
| Laryngeal Neoplasms | 2 | 2023 | 17 | 1.390 |
Why?
|
| Neoplasms | 5 | 2024 | 791 | 1.210 |
Why?
|
| Humans | 43 | 2026 | 34475 | 1.050 |
Why?
|
| Retrospective Studies | 18 | 2025 | 3812 | 0.990 |
Why?
|
| Treatment Outcome | 14 | 2026 | 3618 | 0.880 |
Why?
|
| Radiation Oncology | 1 | 2024 | 14 | 0.870 |
Why?
|
| Vincristine | 1 | 2024 | 25 | 0.860 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 48 | 0.860 |
Why?
|
| Etoposide | 1 | 2024 | 42 | 0.860 |
Why?
|
| Bone Neoplasms | 1 | 2026 | 118 | 0.860 |
Why?
|
| Prednisone | 1 | 2024 | 70 | 0.850 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 19 | 0.850 |
Why?
|
| Contrast Media | 1 | 2025 | 148 | 0.840 |
Why?
|
| Doxorubicin | 1 | 2024 | 91 | 0.830 |
Why?
|
| Prospective Studies | 8 | 2026 | 2461 | 0.830 |
Why?
|
| Pain | 2 | 2025 | 330 | 0.820 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 12 | 0.810 |
Why?
|
| Deglutition | 1 | 2023 | 30 | 0.790 |
Why?
|
| Quality of Life | 5 | 2026 | 1032 | 0.790 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 19 | 0.790 |
Why?
|
| Middle Aged | 23 | 2026 | 12703 | 0.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 489 | 0.780 |
Why?
|
| Prognosis | 11 | 2024 | 1603 | 0.760 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 485 | 0.730 |
Why?
|
| Radiation Injuries | 1 | 2022 | 86 | 0.710 |
Why?
|
| Aged | 18 | 2026 | 10999 | 0.700 |
Why?
|
| Female | 26 | 2026 | 21491 | 0.690 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 222 | 0.670 |
Why?
|
| Male | 26 | 2026 | 20697 | 0.650 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 803 | 0.630 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 95 | 0.630 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 984 | 0.620 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2019 | 7 | 0.610 |
Why?
|
| Papillomaviridae | 1 | 2019 | 23 | 0.610 |
Why?
|
| Lung Neoplasms | 5 | 2025 | 452 | 0.560 |
Why?
|
| Aged, 80 and over | 8 | 2026 | 4151 | 0.520 |
Why?
|
| Adult | 11 | 2026 | 10015 | 0.490 |
Why?
|
| Salvage Therapy | 3 | 2020 | 138 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2025 | 119 | 0.390 |
Why?
|
| Radiodermatitis | 2 | 2024 | 6 | 0.380 |
Why?
|
| Lymph Nodes | 2 | 2023 | 120 | 0.370 |
Why?
|
| Meningioma | 2 | 2020 | 59 | 0.320 |
Why?
|
| Incidence | 3 | 2021 | 1289 | 0.290 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 803 | 0.260 |
Why?
|
| Postoperative Complications | 2 | 2023 | 849 | 0.250 |
Why?
|
| Neuropeptides | 1 | 2025 | 23 | 0.230 |
Why?
|
| Osteoclasts | 1 | 2025 | 25 | 0.230 |
Why?
|
| Sensory Receptor Cells | 1 | 2025 | 37 | 0.230 |
Why?
|
| Radiation Tolerance | 1 | 2025 | 25 | 0.220 |
Why?
|
| Peer Review | 1 | 2024 | 9 | 0.220 |
Why?
|
| Peer Review, Health Care | 1 | 2024 | 8 | 0.220 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2025 | 64 | 0.220 |
Why?
|
| Neck Dissection | 1 | 2024 | 11 | 0.220 |
Why?
|
| Tumor Burden | 1 | 2024 | 64 | 0.210 |
Why?
|
| Preoperative Care | 1 | 2025 | 128 | 0.210 |
Why?
|
| Human papillomavirus 16 | 1 | 2023 | 4 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 24 | 0.200 |
Why?
|
| Survival Analysis | 3 | 2020 | 509 | 0.200 |
Why?
|
| Glottis | 1 | 2023 | 8 | 0.200 |
Why?
|
| Palatine Tonsil | 1 | 2023 | 8 | 0.200 |
Why?
|
| Mastectomy, Segmental | 1 | 2022 | 27 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2022 | 88 | 0.190 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 934 | 0.180 |
Why?
|
| Mastectomy | 1 | 2022 | 64 | 0.180 |
Why?
|
| Cisplatin | 1 | 2022 | 88 | 0.180 |
Why?
|
| Radiotherapy | 1 | 2022 | 90 | 0.180 |
Why?
|
| Brachytherapy | 1 | 2021 | 31 | 0.170 |
Why?
|
| Terminology as Topic | 1 | 2021 | 71 | 0.160 |
Why?
|
| Meningeal Neoplasms | 1 | 2020 | 49 | 0.160 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2020 | 16 | 0.160 |
Why?
|
| Young Adult | 2 | 2024 | 2825 | 0.160 |
Why?
|
| Cell Transformation, Viral | 1 | 2019 | 9 | 0.150 |
Why?
|
| Burns | 1 | 2021 | 103 | 0.150 |
Why?
|
| Plasma Cells | 1 | 2019 | 11 | 0.150 |
Why?
|
| Carcinoma | 1 | 2020 | 97 | 0.150 |
Why?
|
| Syndecan-1 | 1 | 2019 | 20 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 62 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 18 | 0.150 |
Why?
|
| Patient Selection | 1 | 2021 | 291 | 0.150 |
Why?
|
| Melanoma | 2 | 2017 | 169 | 0.150 |
Why?
|
| Risk Assessment | 1 | 2025 | 1506 | 0.150 |
Why?
|
| Histiocytic Sarcoma | 1 | 2018 | 2 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 17 | 0.140 |
Why?
|
| Smoking | 1 | 2022 | 544 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 498 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 2366 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 350 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 627 | 0.100 |
Why?
|
| Survival Rate | 3 | 2020 | 925 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 231 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2024 | 583 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 399 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 633 | 0.060 |
Why?
|
| RANK Ligand | 1 | 2025 | 6 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 589 | 0.060 |
Why?
|
| Ganglia, Spinal | 1 | 2025 | 72 | 0.060 |
Why?
|
| Cell Movement | 1 | 2025 | 180 | 0.050 |
Why?
|
| Cell Survival | 1 | 2025 | 304 | 0.050 |
Why?
|
| Proteomics | 1 | 2025 | 106 | 0.050 |
Why?
|
| Keratins | 1 | 2024 | 42 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 273 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2025 | 484 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 772 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2025 | 628 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 63 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2025 | 765 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2021 | 23 | 0.040 |
Why?
|
| Prostate | 1 | 2021 | 89 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 323 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 116 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2020 | 96 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 170 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 325 | 0.040 |
Why?
|
| Mice | 1 | 2025 | 2691 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 378 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 295 | 0.040 |
Why?
|
| Mediastinum | 1 | 2018 | 14 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 104 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 134 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 176 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 268 | 0.030 |
Why?
|
| Brain Death | 1 | 2017 | 27 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 325 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 155 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1354 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 508 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 117 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 205 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2613 | 0.030 |
Why?
|
| Animals | 1 | 2025 | 8544 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 3799 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 2352 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1910 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 4136 | 0.020 |
Why?
|